Estudio aleatorizado, abierto, multicéntrico, de búsqueda de dosis y duración del tratamiento para evaluar la respuesta virológica mantenida del inhibidor de proteasa VHC Danoprevir (RO5190591) reforzado con Ritonavir en dosis bajas (danoprevir/r) en asociación con Pegasys® y Copegus® comparado con la asociación Pegasys® y Copegus® en pacientes sin tratamiento previo con infección crónica por el virus de la hepatitis C genotipo 1 ó 4. A Randomized, Open label, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir (RO5190591) Boosted with Low Dose Ritonavir (danoprevir/r) in Combination with Pegasys® and Copegus® versus Pegasys® and Copegus® alone in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection Estudiar los efectos de las diferentes dosis y duraciones del tratamiento con danoprevir/r en asociación con Pegasys® y Copegus® sobre la proporción de pacientes que consiguen respuesta virológica man...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study of Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer Estudio de Ipatasertibcon Abiraterona mas Prednisona/prenisolona, comparado con Placebo con Abiraterona mas Prednisona/prenisolona en pacientes adultos masculinos con cancer de próstata metastásico resistente a la castración asintomático o levemente sintomático que no se han tratado previamente • To evaluate the efficacy in the intent to treat (ITT) population • To evaluate the efficacy in patients with PTEN-loss tumors by immunohistochemistry (IHC) -Evaluar la eficacia en la población...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease To investigate the overall response rate and safety data of RO5072759 (1000mg flat dose) given as monotherapy in patients with relapsed CD20+ indolent NHL compared with rituximab(375mg/m2) monotherapy...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open label, prospective, pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir (Tamiflu) in the treatment of infants 0 to <12 months of age with laboratory confirmed influenza infection The primary objective is to define the pharmacokinetics of oseltamivir and oseltamivir carboxylate in children with confirmed influenza up to one year of age.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis The primary objective of this study is to assess whether the efficacy of ocrelizumab 600 mg intravenously every 24 weeks is superior to Rebif® as measured by the annualized protocol-defined relapse r...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase II, Dose-Escalation to rash Trial of Erlotinib (Tarceva®) plus Gemcitabine in Patients With Metastatic Pancreatic Cancer To determine, in patients who do not develop any rash, or develop only grade 1 rash, within 4 weeks of start of treatment with gemcitabine + erlotinib, if overall survival can be improved by increasin...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Copegus for 12 or 24 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection To evaluate the safety, tolerability, and effect on virologicalresponse of a 12 and 24-week duration of RO5190591 incombination with Pegasys and Copegus compared to thecombination of Pegasys and Copeg...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study of RO5083945 in combination with chemotherapy versus chemotherapy alone in patients with advanced or recurrent non-small cell lung cancer To describe by histology group the adverse event profile, pharmacokinetics (PK) and recommended dose of RO5083945 in combination with cisplatin and gemcitabine/pemetrexed To demonstrate by histol...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase III, double-blind, randomized, placebo-controlled, multi-center study evaluating the efficacy and safety of dalcetrapib on lipids, lipoproteins, apolipoproteins and markers of CV risk in patients hospitalized for an acute coronary syndrome (ACS) when treatment is initiated within 1 week after an ACS (dal-ACUTE) -To evaluate the effect of dalcetrapib on high-density lipoprotein C (HDL-C) levels after 4 weeks of treatment when treatment is initiated within one week after an ACS.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to find out the how your body reacts, absorbs, metabolizes and eliminates a combination of drugs and their ability to reduce the activity of a virus that causes permanent inflammation of the liver (Hepatitis C virus) safety, tolerability, pharmacokinetics (PK) and antiviral activity of RO5190591/ritonavir (danoprevir/r) in combination with peginterferon and ribavirin in treatment-naïve genotype 1 or 4 chronic hepa...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune